Discontinue use if symptoms indicative of hepatitis occur. Secondary cause of hyperlipidemia eg, uncontrolled type 2 DM, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, pharmacological treatment, alcoholism; pancreatitis; predisposing factors for myopathy &/or rhabdomyolysis eg, personal or familial history of hereditary muscular disorders. Monitor transaminase levels every 3 mth during 1st 12 mth. Measure creatinine levels during 1st 3 mth & periodically thereafter. Concomitant use w/ HMG-CoA reductase inhibitor. Galactose & fructose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, sucrase-isomaltase insufficiency. Not to be used in severe chronic kidney disease. Not recommended in hepatic impairment. Pregnancy. Not to be used during lactation. Not recommended in paed <18 yr. Elderly >70 yr.